Synthetic Biology grants in the United Kingdom

Awards UK tech innovators cash prizes after free workshops and live pitching.

Between cycles

Supports women founders with a focused programme of mentorship and investor readiness for startup growth.

Between cycles

Supports scaling Scottish technology businesses with hybrid grant-loan funding and growth recognition.

Closed

Turn a public sector research asset into something a market will pay for.

Closed

Supports early-stage founders from Commonwealth countries with mentoring, masterclasses, and investor-facing acceleration.

Pays up to £5,000 to teams solving real-world problems with probabilistic computing.

Pays UK university ventures, startups and SMEs a share of £150,000 in equity-free cash prizes through a national pitching competition.

Awards UK-incorporated innovators up to £650,000 in total -- up to £100,000 as a Finalist, then up to £550,000 more as a Winner -- to develop and scale an innovation for the water sector in England and Wales.

Funds early-stage water-sector innovations with staged seed funding for finalists and winners.

Closed

Offers non-dilutive financing for United Kingdom firms to scale late-stage innovation when standard debt is unavailable.

Closed

Funds Northern Ireland businesses accessing knowledge-provider expertise through GBP 5K innovation vouchers.

Open

Funds researchers combining computational and experimental approaches to test repositioned drugs for Alzheimer's disease treatment through NIH R01 grants.

Open

Funds global vaccine and biologic countermeasure developers to build responses for epidemic pathogens.

Between cycles

Funds developing and validating gene-editing tools in animal and other model systems used to study the human brain.

Between cycles

Funds high-impact collaborative Huntington disease teams tackling complex mechanisms and novel therapeutic strategies with advanced team science.

Pays $100,000, and up to $10 million if patentable, for solving the origin of genetic code.

Between cycles

Funds early-stage life science ventures with seed and Series A equity across therapeutics and medical device innovation.

Closed

Funds organizations conducting clinical trials of vaccine candidates against CEPI priority pathogens and viral families through CEPI's Innovations Call for Proposals.

Awards 15,000 Euro plus exhibition space and mentoring to the winning early-stage company at the ACHEMA Start-up Award 2027, for new ventures in chemistry, process engineering or biotechnology.

Closed

Supports biosecurity research, policy work, and prevention planning for pandemic preparedness.

Closed

Funds organizations designing and early-stage testing of new vaccine candidates against CEPI priority pathogens and Disease X viral families, with awards up to $1M over 18 months.

Closed

Funds organizations conducting preclinical vaccine development for CEPI priority pathogens and Disease X exemplars through CEPI's Innovations call.

Closed

Funds accredited research institutions developing treatments for congenital dystroglycanopathies with grants up to $50,000.

Closed

Funds accredited research institutions developing treatments and care improvements for congenital-onset laminopathies with grants up to $100,000.